Skip to main content

Exposure to Glucocorticoids Increases Risk for New-Onset Diabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 12, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Sept. 11, 2024 -- Exposure to systemic glucocorticoids during hospitalization is associated with an increased risk for new-onset diabetes, according to a study presented at the annual of the European Association for the Study of Diabetes, held from Sept. 9 to 13 in Madrid.

Rajna Golubic, M.D., Ph.D., from the University of Oxford in the United Kingdom, and colleagues estimated the crude and age- and sex-adjusted incidence rate ratio (IRR) of new-onset diabetes arising during time exposed versus unexposed to systematic glucocorticoids. The analysis data set included 451,606 adults free from diabetes (median age, 52 years).

The researchers found that autoimmune/inflammatory diseases/infections were the most common indication for systemic glucocorticoids (65.3 percent). Overall, 1.8 and 0.8 percent of ever-exposed versus never-exposed individuals developed new-onset diabetes in the exposed and nonexposed time in years. The incidence rates were 51.9 and 18.5 per 100 person-years for the ever-exposed and never-exposed groups, respectively. The median length of stay in days was three and one for ever-exposed and never-exposed participants. For new-onset diabetes associated with glucocorticoids, the unadjusted and age- and sex-adjusted IRRs were 2.8 and 2.6, respectively.

"These latest results give clinical staff a better estimate of how likely new diabetes is to occur and could prompt doctors to plan clinical care more effectively to detect and manage new diabetes," Golubic said in a statement.

Abstract

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss

FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...

GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression

MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...

Risk for Death, MACE Increased for Patients With Adult-Onset Type 1 Diabetes

FRIDAY, May 16, 2025 -- Adult-onset type 1 diabetes (T1D) is associated with an increased risk for death and major adverse cardiovascular events (MACE), according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.